Organogenesis (ORGO)
(Delayed Data from NSDQ)
$2.35 USD
+0.07 (2.84%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $2.35 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ORGO 2.35 +0.07(2.84%)
Will ORGO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ORGO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ORGO
Organogenesis (ORGO) Reports Break-Even Earnings for Q4
Foghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last?
ORGO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You Looking for a Top Momentum Pick? Why Organogenesis (ORGO) is a Great Choice
Best Momentum Stocks to Buy for January 5th
New Strong Buy Stocks for January 5th
Other News for ORGO
CETX, ATNI and MNY among mid-day movers
12 Health Care Stocks Moving In Thursday's Intraday Session
Medicare Administrators looking to 'drastically shake up' wound care, says BTIG
MiMedx Group, Cyclacel Pharmaceuticals, Predictive Oncology among healthcare movers
Mimedx Group, Cyclacel Pharmaceuticals, Predictive Oncology among healthcare movers